Scholarlink

<p>Vulvovaginal candidiasis (VVC) affects millions of women globally and is characterized by multifactorial immunopathology, with <i>Candida albicans</i> virulence driving disease progression through epithelial tissue damage and neutrophil hyperactivation and dysfunction contributing to disease severity. Here, we explored the multifaceted nature of <i>S. cerevisiae</i> as a live-biotherapeutic to attenuate <i>C. albicans</i> virulence and modulate host immune responses during VVC. We identified an <i>S. cerevisiae</i> isolate (Sc3458) that targets multiple aspects of <i>C. albicans</i> virulence, including fungal proliferation, adhesion, and hyphal morphogenesis, collectively impairing biofilm formation and disrupting pathogenic potential. These effects were linked to transcriptional reprogramming in <i>C. albicans</i>, marked by metabolic stress and downregulation of virulence- and biofilm-related genes. Additionally, <i>S. cerevisiae</i> (Sc3458) reduced inflammatory responses and neutrophil hyperactivation, while preserving neutrophil antimicrobial functionality. Altogether, this translated to an improved control of infection and dampened VVC-associated hyperinflammation in a murine VVC model. These findings position <i>S. cerevisiae</i> strain Sc3458 as a promising candidate live biotherapeutic for VVC treatment. Further clinical validation in human cohorts is essential to confirm its therapeutic efficacy and to assess how Sc3458 performs relative to established market-standard formulations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Mart Sillen,
  • Dania El Abyad,
  • Nina Vreys,
  • Silke Baldewijns,
  • Ilse Palmans,
  • Odessa Van Goethem,
  • Kar On Cheng,
  • Greetje Vande Velde,
  • Dolly E. Montaño,
  • Nele Berghmans,
  • Mieke Gouwy,
  • Agustin R. Sharpe,
  • Lies De Groef,
  • Axel Dietschmann,
  • Paul Vandecruys,
  • Sarah Lebeer,
  • Liesbeth Demuyser,
  • Mark S. Gresnigt,
  • Patrick Van Dijck

摘要

Vulvovaginal candidiasis (VVC) affects millions of women globally and is characterized by multifactorial immunopathology, with Candida albicans virulence driving disease progression through epithelial tissue damage and neutrophil hyperactivation and dysfunction contributing to disease severity. Here, we explored the multifaceted nature of S. cerevisiae as a live-biotherapeutic to attenuate C. albicans virulence and modulate host immune responses during VVC. We identified an S. cerevisiae isolate (Sc3458) that targets multiple aspects of C. albicans virulence, including fungal proliferation, adhesion, and hyphal morphogenesis, collectively impairing biofilm formation and disrupting pathogenic potential. These effects were linked to transcriptional reprogramming in C. albicans, marked by metabolic stress and downregulation of virulence- and biofilm-related genes. Additionally, S. cerevisiae (Sc3458) reduced inflammatory responses and neutrophil hyperactivation, while preserving neutrophil antimicrobial functionality. Altogether, this translated to an improved control of infection and dampened VVC-associated hyperinflammation in a murine VVC model. These findings position S. cerevisiae strain Sc3458 as a promising candidate live biotherapeutic for VVC treatment. Further clinical validation in human cohorts is essential to confirm its therapeutic efficacy and to assess how Sc3458 performs relative to established market-standard formulations.